ArticleMolecular vision2024
A potential novel role of the R36P mutation in CRYGD in congenial cataract.
Article in Molecular vision, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Congenital cataract is an important cause of visual impairment in childhood. Our previous study reported that the c.110G>C (p.R36P) mutation in the γD-crystallin gene (CRYGD) was associated with congenital cataract in a Chinese family. This study aimed to investigate the potential underlying mechanism through which the p.R36P mutation leads to congenital cataract. Methods: Plasmids encoding wide-type human γD-crystallin and the mutant R36P γD-crystallin were transfected into HEK293T and SRA01/04 cells. Protein expression levels, including total, soluble, and insoluble fractions, were quantified by Western blotting. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) was used to assess the mRNA expression of other crystallin genes. Cell viability and apoptosis were evaluated using the CCK-8 assay and flow cytometry, respectively. Results: The total protein, especially the soluble fraction, was significantly reduced in the R36P mutant, while the insoluble part remained unaffected. The decrease of soluble R36P γD-crystallin could not be rescued by the proteinase inhibitor MG132. The mRNA expression of the R36P mutation was lower, but other crystallin RNAs were unchanged. Cell viability was slightly decreased (11%, p<0.05), and cell apoptosis was not significantly increased (12%, p=0.31). Conclusions: The significant decrease in soluble R36P γD-crystallin may represent a novel mechanism underlying congenital cataract caused by CRYGD gene mutation.
Indexed as
Identifiers
39563676PMC11575838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.